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A systemic graft-vs.-host reaction (GVHR) 1 induced in nonirradiated recipients can 
give rise to a  variety of pathological symptoms. One of the possible outcomes is acute 
GVH  disease  (GVHD).  After an  initial brief phase  of lymphoid stimulation  (1-3), 
acute GVHD  rapidly produces suppressive pathological symptoms, such as pancyto- 
penia accompanied by aplastic anemia and hypogammaglobulinemia (1-5). A  differ- 
ent  possible consequence  of the  GVHR  is  stimulatory GVHD,  also  referred  to  as 
chronic  GVHD.  The  symptoms  of chronic  GVHD  include  a  persistent  lymphoid 
hyperplasia  (1-4,  6),  hypergammaglobulinemia  (2-4,  7,  8),  and  the  formation  of 
autoantibodies and pathological lesions reminiscent of systemic lupus erythematosus 
(SLE) and other types of vascular collagen disease (2, 3, 6, 8, 9). 2' 3 
Both  types of GVHD  can  be experimentally induced in  nonirradiated F1 hybrid 
recipients by the injection of lymphocytes from one of the parental strains. A common 
requirement for the induction of both acute and chronic GVHD  is the presence of T 
lymphocytes in  the  donor-cell inoculum  (3-5,  8,  9). 2, 3 Which  type of GVHD  will 
develop after the injection of parental T  cells appears to depend on  the functional 
subset of donor T  cells activated in the F1 host. Work from this laboratory has shown 
that  the stimulatory type of GVHD  can  be induced by alloreactive donor T  helper 
(TH) cells (2-5, 8, 9) carrying the Lyt-1 +2- phenotype,  3 whereas the induction of acute 
GVHD  requires  both  alloreactive TH  and  T  suppressor  (Ts)  cells  (2-5). 3  In  the 
development of acute GVHD, there appears to be a sequential activation of these two 
subsets of donor T  cells: first, alloreactive TH cells induce the brief initial phase  of 
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stimulatory symptoms (week 1) and, then (week 2) help to activate the alloreactive Ts 
cells (2, 3). The alloreactive donor Ts cells appear to be the final effector cells causing 
the rapidly developing suppressive symptoms of acute GVHD  (2-5). 
Apart from the requirement of donor T  cells, another common denominator for the 
induction of both types of GVHD is that an H-2 incompatibility between donor and 
nonirradiated  F1 host  is  required  (3,  5). z Several  groups have studied  the  intra-H-2 
differences required  for the induction of GVHR  (10-15). These studies were limited, 
however,  to  the  use  of the  popliteal  lymph  node  weight  assay  (15)  and  the  spleen 
weight  assay  (11-14),  which  were  performed  at  a  single  point  in  time,  and  to the 
mortality  assay  (12-15).  The  results  obtained  show  that  a  strong  spleen  weight 
increase as well as a strong popliteal lymph node weight increase is induced across an 
I region difference and that only a  weak or moderate increase is induced across K  or 
D  region  incompatibilities  (10,  14).  Using  irradiated  F1  mice  as  recipients,  the 
mortality rate was found to be maximal across a  total H-2 difference (15). Moderate 
mortality rates were found when  donor and host  differed  at  either K, I, or D  alone 
(15). 
From studies  on the  primary antibody response  in  vitro,  on the other hand,  it  is 
known that class II (I-A/I-E) alloantigens preferentially trigger alloreactive TH cells, 
which cause  the positive  allogeneic effect  (16),  4 and  that  class-I  (K/D)  alloantigens 
preferentially trigger alloreactive Ts cells, causing the negative allogeneic effect (16).4 
In the present investigation, using GVH assays that are able to measure both allohelp 
and  allosuppression,  we studied  whether  the  functional  dichotomy between  class  I 
and class II alloantigens exists also in vivo. We asked whether well-defined differences 
in  class  I  and/or  class  II  alloantigens  can  selectively  activate,  out  of a  pool  of 
unselected donor cells, the subpopulation(s)  of T  cells that cause either stimulatory or 
suppressive GVHD. The strains of mice used for this study were C57BL/6  (B6), the 
B6 mutant strain  B6.C-H-2 bma  (bml), which carries a  mutation  at the K  locus  (17), 
and the B6 mutant  strain B6.C-H-2  bmx2 (bml2),  which carries a  mutation at the I-A 
locus of H-2 (18). The results show that, indeed, the dichotomy observed in vitro (16) 4 
also exists in vivo. An exclusively stimulatory GVHD was induced across a difference 
at  I-A alone,  whereas  the  induction  of suppressive  GVHD  required  a  difference  at 
both  I-A  and  K.  By  contrast,  the  K  locus  difference  alone  was  insufficient  for 
triggering clear-cut symptoms of either stimulatory or suppressive GVHD. 
Materials  and Methods 
Mice.  B6 mice were purchased from Olac 1976 Ltd. (Bicester, Oxon, England). The H-2K  b 
mutant strain bm 1 (17) was originally obtained from Dr. D. W. Bailey (The Jackson Laboratory, 
Bar Harbor, ME). The H-2 LA  b mutant strain bml2 (18) was originally obtained from Dr. R. 
W.  Melvold  (Northwestern  University,  Chicago,  IL).  Both  strains  were  maintained  at  our 
laboratory by sibling-to-sibling matings. The F1 hybrid mice (B6 ×  bml),  (B6 ×  bml2), and 
(bm 1 × bm 12) were bred in our animal facilities.  Sex-matched donor and recipient mice, 8-12 
wk old, were used. 
Preparation of Donor Cells.  Single-cell  suspensions of spleen and lymph node cells of B6 donors 
were prepared as described (5). 
Induction of GVHR.  In experiment I, (B6 X bml)F1, (B6 ×  bml2)F1, and (bml  ×  bml2)Fx 
hybrid mice received a total of 108 viable B6 cells consisting of one-third lymph node cells and 
4 Rolink, A. G., W. van der Meer, C. J.  M. Melief, and  E. Gleichmann. 1983. Intra-H-2 and T cell 
requirements for the induction of maximal positive and negative allogeneic effects in vitro. Eur.  J. Immunol. 
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two-thirds spleen cells;  these cells were administered intravenously in two equal dosages  on 
days 0 and 7. In experiment II, the three kinds of F1 hybrid mice received a single intravenous 
injection of 108 viable B6 spleen cells. Age- and sex-matched noninjected F1 (N F1) mice of the 
three strains were used as controls. 
Protein A Plaque-forming Cell Assay.  To determine the total number of Ig-secreting cells in the 
spleens of N  F1  mice  and  in  the  spleens of F1  mice  undergoing a  GVHR  (GVH  F1), a 
modification of the protein-A plaque assay was performed as described (19). 
Prima~y In  Vitro Anti-sheep E~ythrocyte (SRBC)  Response.  On day 0, a constant number of 5 
×  106 spleen cells obtained from N  F1 animals were co-cultured with SRBC and increasing 
numbers of spleen cells derived from GVH F1 mice (2, 20). Cultures were performed in Falcon 
multi-well tissue-culture plates  (3008;  Falcon Labware, Oxnard, CA)  containing 500  /xl of 
culture medium. The latter consisted of Iscove's  modified Dulbecco's medium supplemented 
with 10% fetal calf serum, penicillin (50 IU/ml), streptomycin (50 IU/ml), and 2-mercaptoeth- 
anol (2 ×  10  -5 M). 
Clinical Signs of G VHR.  Twice a week, the GVH F1 were inspected for symptoms of acute 
GVHD, such as weight loss, diarrhea, and ruffled fur. The number of dead mice was recorded. 
Anemia was  determined by biweekly measurement of hematoerit. At weekly intervals, the 
GVH F1 mice were tested  for elevated proteinuria (->300 mg protein per  100 ml urine) by 
means of Albustix test sticks (2872; Miles Laboratories, Ames Div., Elkhart, IN). Previously it 
has  been shown  (21)  2 that  elevated proteinuria is  a  reliable indicator of immune-complex 
glomerulonephritis (ICGN) in GVH F~ mice. 
Detection of Autoantibodies.  IgG autoantibodies to  erythrocytes were  detected  by a  direct 
Coombs' test using a 1  : 100 diluted, heat-inactivated rabbit-anti-mouse  IgG serum, as described 
(8). Serum autoantibodies  to thymocytes were detected by a complement-dependent  cytotoxicity 
test (8), in which ~lCr-labeled thymocytes from normal B6 mice were used as target cells. Mice 
were scored positive for autoantibodies against thymocytes when a  1:5 dilution of their serum 
lysed _>40% of the target cells. Serum IgG antibodies against nuclear antigens were detected by 
an indirect immunofluorescence  technique, applying fluorescein-labeled  rabbit-anti-mouse  IgG 
serum; cryostat sections of mouse liver were used as antigenic substrate, as described (8). Serum 
IgG autoantibodies against double-stranded DNA (dsDNA) were determined by an indirect 
immunofluorescence technique applying a  fluorescein-labeled goat-anti-mouse IgG  (Meloy 
Laboratories Inc., Springfield, VA); the extranuclear dsDNA of the hemoflagellate Crithidia 
luciliae was  used as antigenic substrate, as  described (8,  22).  For the determination of both 
antinuclear and anti-dsDNA antibodies, the initial serum dilution was 1  : 10; the highest serum 
dilution at which specific immunofluorescence  was seen was called the titer. 
Determination of ICGN.  At autopsy, one kidney of each GVH Fa hybrid was snap-frozen and 
stored in liquid nitrogen. Cryosections, 4/tm thick, were prepared and incubated for 30 min 
with a  1:60 dilution of rabbit-anti-mouse  IgG labeled with fluorescein isothiocyanate (KM 16- 
1  l-F3; Central Laboratory of the Netherlands Red Cross  Blood Transfusion Service).  After a 
wash with  phosphate-buffered saline for  30  min, the sections were  mounted with glycerol, 
diluted 1:2 phosphate-buffered saline, and examined in a Leitz Orthoplan microscope. 
Statistical Significance.  Student's t test was applied. 
Results 
The Capacity of B6 Donor Cells to Induce  Lethal GVHD  (LGVHD)  Requires a Difference 
in the Ft Recipients at Both I-A and K.  Groups ofnonirradiated (bml ×  bml2)F1, (B6 
×  bml)F1, and (B6 X bl2)F1 mice were injected intravenously with  108 B6 cells; the 
donor-cell inoculum consisted of two parts of spleen and one part of lymph node cells. 
After initiation of the GVHR, the (bm 1 X bm 12)F1 recipients, which differ from the 
B6  donor  strain  by  mutations  at  both  the  K  and  I-A  locus,  all  developed  the 
characteristic  symptoms  of  acute  GVHD,  including a  reduced  body  weight  and 
reduced hematocrit values (Table I), and died (Fig.  1). In marked contrast, none of 
the (B6 ×  bml)Fa recipients, which differ from the B6 donor strain by a  mutation at 
the K  locus alone, died from or showed clinical symptoms of acute GVHD  (Fig.  1, 758  GRAFT-VS.-HOST  DISEASE  MUTATIONS  AT  tt-2K  AND/OR  I-A 
TABLE  I 
Body Weight and Hematocrit Values of the Three Kinds of F~ Mice at Different Times 
after the Induction of GVHR 
Weeks after the initiation of GVHR 
GVH F1 mice 
tested and H-2 
difference 
indicated1: 
-1  3  8 
Mean body  Mean hem-  Mean body  Mean hema-  Mean body  Mean hema- 
weight -4-  atocrit -4-  weight +  tocrit +  weight +  tocrit 4- 
SEM  SEM  SEM  SEM  SEM  SEM 
g  g  g 
(bml X bml2)F1  20.5 +- 0.4  43.4  +  0.2  17.0 +  0.5§  34.4 +  0.6§  II  II 
K+  I-A 
(B6 ×  bml)F~  20.0 -4- 0.7  42.7  -4- 0.6  22.0 4- 0.6¶  43.0  +  0.3**  21.7 _  0.6¶  43.1  -4- 0.5** 
K 
(B6 ×  bml2)F~  20.1 +  0.6  42.1 -4- 0.2  22.7 +  0.3¶  42.3  +  0.4**  24.7 _+ 0.7¶  42.3  +_ 0.6** 
I-A 
* 1 wk before the initiation of GVHR. 
:~ GVHR was induced by intravenous injection on days 0 and,7 of a mixture of 5 X 107 live B6 donor cells 
containing one-third lymph node cells and two-thirds spleen cells, 
§ Significantly lower (P <  0.05)  when compared with the corresponding values at week -  1. 
II All (bml X bml2)Fl recipients had died from acute GVHD by this time (Fig.  1). 
¶ Significantly higher (P <  0.05)  when compared with the corresponding values at week -  1. 
** Not significantly different (P >  0.05)  from the corresponding values at week -1. 
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weeks  after  first  injection  of B6  donor  cells 
FIO.  1.  Induction  of LGVHD  in  the three kinds of F~  mice. Groups  of Ft  mice were injected 
intravenously on days 0 and 7 with a mixture of 5 X  107 viable B6 donor cells containing one-third 
lymph node cells and two-thirds spleen cells. (O), GVH  (B6  ×  bml2)Fl mice (group of 13 mice); 
(O), GVH  (B6 X bml)F1 mice (group of 14 mice); (A), GVH  (bml  X bm12)F1  mice (group of 15 
mice). 
Table  I).  Likewise,  none  of the  (B6  X  bml2)F1  recipients,  which  differ from  the  B6 
donor  strain  by  a  mutation  at  the  I-A  locus  alone,  died  from  or  showed  clinical 
symptoms  of acute  GVHD  (Fig.  1,  Table  I). 
The  Capacity  of B6  Donor  Cells  to  Induce  a  Systemic  Lupus  Erythematosus  (SLE)-like 
Stimulato~y GVHD Requires a Difference in the F1 Recipients at I-A Alone.  The  same  group 
of nonirradiated  F1  recipients  studied  for  the  induction  of LGVHD,  were  tested  for 
the  presence  of  SLE-like  autoantibodies  in  the  serum,  elevated  proteinuria  as  an 
indication  of severe ICGN  (21), z and  immunohistological  evidence  of ICGN. 
1  wk  before  the  induction  of  the  GVHR,  none  of  the  F1  mice  had  detectable 
amounts  of autoantibodies  in  their  serum  or elevated  proteinuria  (Table  II).  In  the T
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time period between the induction  of GVHR and death due to acute GVHD, none 
of the (bml ×bm 12)F1 recipients produced detectable amounts of autoantibodies or 
had  elevated  proteinuria  (Table  II).  Thus,  the  B6  donor  cells  were  incapable  of 
inducing any symptoms of SLE-like GVHD in recipients differing at both I-A and K. 
Also,  none  of the  (B6  ×  bml)F1  recipients,  which  differed  at  the  K  locus  alone, 
produced detectable amounts of autoantibodies early during the GVHR; at weeks 8 
and  14 only, one-third of these GVH F1 mice had antibodies against nuclear antigens 
and 25% had antibodies against dsDNA  (Table II). Furthermore, none of the GVH 
F1  mice of this  group had antibodies  against  thymocytes in  their serum or became 
Coombs' positive at any of the time points tested,  and,  significantly,  none of them 
developed elevated proteinuria. These findings indicate that an incompatibility at K 
alone was insufficient to trigger a full-blown SLE-like syndrome, but, if at all, induced 
only mild symptoms of chronic GVHD. 
By contrast, 2 wk after the initiation of GVHR the vast majority of the I-A-different 
(B6 ×  bm12)F1 recipients showed autoantibodies to thymocytes and nuclear antigens, 
and,  during  the  course  of  the  GVHR,  all  (B6  ×  bml2)F1  recipients  had  these 
autoantibodies  at one or more of the times tested  (Table II). IgG autoantibodies  to 
dsDNA  were  detectable  from  week  4  onwards,  and  67%  of the  (B6  ×  bml2)Fi 
recipients showed these antibodies at one or more times during the GVHR. Moreover, 
42% of the GVH F1 mice were Coombs' positive at one or more of the times tested. 
Elevated proteinuria occurred  in  50% of the GVH  (B6  ×  bml2)F1  recipients.  One- 
half of the mice with elevated proteinuria also developed ascites, indicating that these 
GVH F1 mice had a severe nephrotic syndrome. Those GVH (B6 ×  bm 12)F1 recipients 
which had elevated proteinuria also showed immunohistological evidence of ICGN. 
Thus, incompatibility at I-A alone elicited a full-blown SLE-like GVHD. 
B Cell Activity in the Spleens of the Three Kinds ofGVH FI Mice.  As reported previously 
(2),  nonirradiated,  H-2-different F1 mice developing acute GVHD initially  (week  1) 
showed a phase of strong B cell stimulation, which rapidly thereafter (week 2,) reversed 
to severe B cell suppression. By contrast, Fa mice undergoing chronic GVHD showed 
a continuing stimulation of their B cells (2). These observations were made in groups 
of identical F1 mice that had been injected with genetically different T  cells obtained 
from  one  of the  two  parental  strains,  C57BL/10  and  DBA/2,  respectively.  Very 
similar results were made in the present study, where we injected genetically identical 
donor cells into groups of F1 recipients that carried different H-2 mutations. 
Groups of (bml ×  bml2)Fl, (B6 X bml)Fa, and (B6 ×  bml2)Fa mice were injected 
with  l0  s B6 spleen cells.  After 7 and  17 d, the spleen cells from the GVH F1 mice of 
these  groups  were  assayed  for  the  total  number  of IgG- and  IgM-secreting cells. 
Groups of syngeneic N  F1 mice served as controls. At  7 d  after the initiation  of the 
GVHR, the numbers of IgG- and IgM-secreting cells per  106 spleen cells of the K- 
and I-A-different (bml ×  bml2)F~ recipients were increased by factors of ~5.5 and 2, 
respectively (Table  III). In  addition,  the  spleen  weights  of these  GVH  F1  animals 
were increased by a factor of 2.4 (Table IV). At 17 d after the initiation of the GVHR 
in such F1  mice, however, the numbers of IgG- and IgM-secreting spleen cells were 
decreased  by  a  factor  of 3-4  (Table  III),  although  the  spleen  weights  were  still 
increased  (Table IV). These findings indicate that induction  of the GVHR in  (bml 
×  bml2)Fx recipients, which differed by mutations at both I-A and K, initially (week ROLINK  ET  AL.  76 1 
TABLE  III 
Numbers of IgM- and IgG-secreting Cells in the Spleens of the Three  Kinds of Ft Mice at Different Days 
after the Induction of GVHR 
Mice tested and H-2 difference indicated 
Mean number (_ SEM) of protein A PFC (×  10  a) per l0  s 
nucleated spleen cells at indicated days after the induction of 
GVHR 
GVH FI*  N F1~ 
Day 7  Day 17 
IgM  IgG  IgM  IgG 
(bml × bml2)Fa  1.6 ±  0.3§  6.7 ±  2.5§  0.2 ± 0.0611  0.3 ± 0.0711 
K +  I-A  (bml X bml2)Fl  0.8 ±  0.1  1.2 4- 0.2  0.6 ± 0.1  1.2 ±  0.1 
(B6 × bml)F1  0.9 +- 0.1¶  0.8 +_- 0.1¶  0.8 ± 0.1¶  0.8 ± 0.2¶ 
K  (B6 X bml)F~  0.6 ± 0.1  0.6 ± 0.2  0.6 ± 0.2  0.6 ± 0.1 
(B6 ×bm 12)F1  1.3 _+ 0.1§  5.5 --- 0.8§  3.1 ± 0.4§  5.2 ± 0.9§ 
I-A  (B6 X bml2)Fl  0.8 ± 0.2  1.0 --- 0.1  0.9 ± 0.2  0.9 ±  0.2 
* GVHR was induced by intravenous injection of 108 viable B6 spleen cells on day 0. Each group consisted 
of five mice. 
:~ Noninjected F1 mice. Each group consisted of five mice. 
§ Significantly  higher (P <  0.05) when compared with the values of the corresponding N F1 mice. 
II Significantly  lower (P <  0.05) when compared with the values of the corresponding N Fa mice. 
¶ Not significantly  different from the values of the corresponding N Fl mice. 
TABLE  IV 
Spleen Weights of the Three Kinds of F1 Mice at Different Times after the Induction of GVHR 
Mice tested and H-2 difference indicated  Spleen weights of the FI mice* at indicated time 
after the initiation of GVHR 
GVH Fa:~  N F~§  Day 7  Day 17 
mg 
(bml X bml2)F1  305 ±  1511  ¶  308 ±  12¶ 
K +  I-A  (bml X bml2)F~  128 +  10  122 -4- 4 
(B6 X bml)Fl  115 --- 8**  202 __. 30¶ 
K  (B6 ×  bml)F~  120 +  9  125 +  2 
(B6 × bm12)Fl  140 +  10"*  419 +  25¶ 
I-A  (B6 ×  bml2)h  117 ± 8  i20 +  24 
* Five mice per group. 
GVHR was induced by intravenous injection of 10  s viable B6 spleen cells on day 0. 
§ Noninjected F1 mice. 
[1  Arithmetic mean +  SEM. 
¶ Significantly  higher (P <  0.05) than the values of the corresponding N Fa mice. 
** Not significantly  different  (P >  0.05) from the values of the corresponding N Fl mice. 
1)  led to a  strong B-cell stimulation which rapidly thereafter (week 3)  changed  into 
suppression. 
At  7 d  after the initiation of GVHR  in  (B6  ×  bml)F1 mice, which differed by the 
K  mutation  only,  the total  numbers  of IgG- and  IgM-secreting cells per  10  n spleen 
cells were  not  significantly different from  the  numbers  found  in  the spleens of the 
corresponding N  F1 mice (Table III). The spleen weights of these GVH  Fa mice were 
not significantly different from the spleen weights of N  F1  mice (Table IV). At  17  d 762  GRAFT-VS.-HOST  DISEASE MUTATIONS AT  H-2K  AND/OR  I-A 
after the initiation of the GVHR, the numbers of IgG- and IgM-secreting cells were 
per  106 spleen cells slightly but not significantly increased. The mean spleen weight 
of these GVH F1 animals was increased by a factor of 1.6 (Table IV). Thus, B6 donor 
cells induced  neither  a  strong stimulation  nor suppression  of the  B  cells in  the  K- 
different (B6 ×bm 1)F1 recipients, and only a marginal splenomegaly was induced in 
these F1 recipients. 
7 d after the induction of the GVHR in the I-A-different (B6 ×  bml2)F1 mice, the 
number of lgG-secreting cells per 106 nucleated spleen cells was increased by a factor 
of 5.5,  and  the total number of IgM-secreting cells by a  factor of about  1.6  (Table 
III). At this point in time, the spleen weights of the GVH (B6 ×  bml2)F1 mice were 
not  different  from those of the corresponding N  F1  mice (Table IV).  17 d  after the 
initiation of the GVHR, the numbers of IgG- and IgM-secreting cells per  106 spleen 
cells were increased by a  factor of 5.7  and 3.4, respectively (Table III). At that time, 
the spleen weights of the (B6 ×  bml2)Fa recipients were increased by a  factor of 3.5 
(Table IV), and  the numbers of nucleated  cells in  the  spleens were increased  by a 
factor of -2 when compared with the numbers in the spleens of N F1 mice. Therefore, 
the total numbers of IgG- and  IgM-secreting cells in the spleens of (B6  ×  bml2)Fa 
recipients were, in fact, increased by factors of 11 and 7. These findings indicate that 
B6 donor cells failed to suppress and exclusively stimulated  the  B  cells of the  I-A- 
different  (B6 ×  bml2)Fl  recipients.  Moreover, the number of IgG-secreting cells in 
the spleens of the GVH  (B6  ×  bml2)F1  mice, used  for the  induction  of acute  and 
chronic GVHD (Fig.  1; Tables I and II), was increased by a  factor of ~3 at time of 
autopsy (day 112 after the induction of the GVHR)  (data not shown). This indicates 
300 
100 
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o  I  116  3'.2  6.4  12.8  2s  so 
GVH spleen cells added  (xtO  4) 
FIe.  2.  Addition  of graded  numbers of spleen  cells  obtained  from  GVH  FI  mice  to  SRBC- 
stimulated cultures of 5 X l0  G  spleen cells from syngeneic N Fa mice.  The GVHR had been induced 
10 d before by injecting into the three kinds of F1 mice l0  s spleen cells from B6 donors. Anti-SRBC 
plaque-forming cells  (PFC)/culture were determined on day 4 and plotted as percent of PFC of 
control cultures to which no GVH spleen cells had been added [(B6 X bm 12)F~: 100% =  740 PFC/ 
culture [C)]; (B6  ×  bml)Fj:100%  =  1460 PFC/culture  [O];  (bml  ×  brnl2)Fj:100%  =  762  PFC/ 
culture I/X])  1. Each point represents the mean +  SD of four cultures. (C)), spleen cells from GVH (B6 
×  bml2)Fl  mice added  to spleen cells  from normal  (B6  X  bm12)Fl  mice;  (O),  spleen cells  from 
GVH (B6 ×  bmt)F1 mice added  to spleen cells from normal (B6 X bml)F1 mice;  (/X), spleen cells 
from GVH (bml ×  bml2)Fl mice added to spleen cells from normal (bin1  ×  bm12)Fj mice. ROLINK  ET  AL.  763 
that  B6 donor cells induced a  persistent stimulation of IgG-secreting B cells in  (B6 
×  bm 12)F1 recipients that differed by the I-A mutation only. 
The Activity of Alloreactive Donor Tn and Ts Cells in the Spleens of the Three Kinds of GVH 
FI Mice.  It has been shown (2, 20)  that spleen cells obtained from nonirradiated F1 
mice  suffering  from  acute  GVHD  (weeks  2-4)  suppress  the  primary  anti-SRBC 
response of normal  Fa spleen cells in vitro. This suppression was due to Fl-specific 
alloreactive donor Ts cells (20,  23,  24), the activity of which peaked around day  10 
after the initiation of the GVHR (2, 20). By contrast, spleen cells from GVH F1 mice 
suffering from stimulatory GVHD failed to suppress the primary anti-SRBC response 
of normal F1 spleen cells in vitro (2). To more precisely determine the alloantigens to 
which donor TH and Ts cells, respectively, react, spleen cells obtained from the three 
kinds of mutant GVH F1 mice were also tested in such an assay system. 
As few as 6.4 ×  104 spleen cells obtained from GVH (bml ×  bml2)Fa mice almost 
completely suppressed the primary anti-SRBC response of 5  ×  l0  G normal  (bml  × 
bml2)F1 spleen cells (Fig. 2). Thus, a mutation in the F1 recipients at both K  and I- 
A  had  led  to maximal  activation of B6  allosuppressor T  cells in  week 2  after the 
induction of the GVHR. Spleen cells from GVH (B6 ×  bml)F1 mice, which differ at 
the K  locus only, also suppressed the primary anti-SRBC of normal  (B6 ×  bml)Fa 
spleen cells.  This suppression, however, was  far less  profound when compared with 
the suppression  induced by GVH  (bml  ×  bml2)F1  spleen ceils.  Spleen cells  from 
GVH  (B6  ×  bml2)Fa  mice  failed to suppress  but  helped  the  primary anti-SRBC 
response of normal (B6 ×bm 12)F1 spleen cells. Thus, a mutational difference between 
donor and  host  at  I-A alone appears  to exclusively activate alloreactive donor TH 
cells. 
Discussion 
There is  increasing evidence that  functionally different subsets  of donor T  cells, 
which may act synergistically as well as antagonistically, are responsible for the wide 
spectrum of different pathological GVH symptoms (2-5, 8, 9, 20, 23, 25).  3 Hence, in 
attempts to dissect the cellular mechanism  underlying stimulatory and suppressive 
GVH  symptoms,  respectively,  it  is  crucial  that  assays  be  used  which  reflect  the 
different and sometimes even antagonistic functions of subsets of donor T  cells.  The 
spleen  weight  assay  and  the  popliteal  lymph  node  weight  assay  do  not  measure 
specific cellular function and preferentially reflect stimulatory rather than suppressive 
activities of donor T  cells.  The GVH mortality assay, too, is inadequate because, at 
least in nonirradiated recipients, it reflects the activity of alloreactive donor Ts cells 
(4), but does not measure allohelp. Moreover, GVH mortality can greatly vary due to 
nonimmunological factors, such as the quality of the microflora in the intestine of the 
recipients (2, 26). 
A GVH assay by which one can measure the activity of both alloreactive donor TH 
and Ts cells has been described by Pickel and Hoffmann (20,  23). By using a parent 
F1  hybrid  combination  differing at  all  of H-2,  they  showed  that  spleen  cells 
obtained from GVH F1 mice on day 3 after the initiation of GVHR exerted a positive 
allogeneic effect on the primary anti-SRBC response of N  F1 spleen cells in vitro; by 
contrast, spleen cells obtained on days 7-20 exerted a negative allogeneic effect (20, 
23). Allohelp in this system was provided by Fl-specific Lyt-1  +2- donor T cells present 
in the spleens of the GVH Fa mice (20, 23), whereas allosuppression was caused by F1- 764  GRAFT-VS.-HOST DISEASE  MUTATIONS AT tt-2K AND/OR  I-A 
TABLn V 
Summary of the Presented Data 
GVH F1 mice 
tested and H-2 dif- 
ference indicated* 
Number of Ig-secreting 
cells in the spleen at indi- 
cated time after the initia- 
tion of GVHR:~ 
Day 7  Day 17 
Effect of GVH F1  Clinical signs  spleen cells on the  SLE-like auto-  of acute  primary anti-  antibodies and  GVHD and in- 
SRBC response of  elevated pro-  duction of 
N F1 spleen cells in  teinuria[I  LGVHDI  { 
vitro (day 10)§ 
(B6 x  bmt2)F,  ~  1"  1'  +  - 
I-A 
(B6 × bml)F~  0  0  0/1,  ---  - 
K 
(bml × bml2)F1  1'  J,  ~,  -  + 
K+  1-A 
* GVHR was induced by injection of B6 lymphocytes. 
:~ 0, No increase or decrease; ]', increase; ~, decrease. 
§ 1", help; 0/~,, weak suppression; ~,, strong suppression. 
[[ -, Absent; ±, weakly present or absent; +, present. 
specific  Lyt-l+2  +  donor  T  cells  (20,  23,  24).  In  a  preliminary  report  from  our 
laboratory, the results obtained by this assay system were found to correlate with the 
histopathological  changes  taking  place  in  the  lympho-hemopoietic  tissue  of  H-2- 
different GVH  F1 mice. It was shown  that  the activation of allosuppressor donor T 
cells preceded and  coincided with  the pancytopenia characteristic of acute  GVHD 
(2). In addition, the protein-A PFC assay (19) was used as an indicator of total B  cell 
activity  in  the  spleens  of the  GVH  Fa  mice.  This  assay,  too,  clearly reflected  the 
sequential activation of first allohelper and then allosuppressor donor T  cells during 
the first 3 wk after the initiation of the GVHR  (2). 
In the present investigation, the results obtained in H-2-mutant GVH  F1 mice by 
means of the Pickel and Hoffmann assay and the protein-A PFC assay were compared 
with those obtained by more conventional GVH  assays. A  mutational difference, in 
the F1 recipient, solely at I-A was shown  to activate exclusively allohelper T  cells of 
the B6 donor and led to a  continuous production of stimulatory GVH  symptoms. By 
contrast, a  mutational difference at both I-A and K  led to the sequential activation 
of  B6  allohelper  and  allosuppressor  T  cells.  This  rapid  sequence  of  differential 
alloactivation in  vivo was  closely paralleled by  stimulatory and  suppressive GVH 
symptoms, respectively, as measured by more conventional GVH assays. A mutational 
difference at  K  alone, however,  failed to optimally activate either the allohelper or 
the allosuppressor T  cells of the B6 donor. The results of our studies are summarized 
in Table V. 
Induction of an SLE-like Stimulatory  GVHD across an I-A Mutation.  The bml2  mutant 
is of the gain and loss type (27), maps to the I-A subregion  (18), and consists of but 
a  limited number of peptide differences in the Aft polypeptide when compared with 
B6 (28). Functional studies have shown that the mutation resulted in strong reciprocal 
mixed lymphocyte reactions (18) and the generation of cytotoxic T  cells (29) between 
B6 and bm 12. By studying the genetic requirements for the induction of abnormal T- 
B  cell cooperation  in  vitro,  we  found  that  B6  T  ceils can  optimally help  (positive 
allogeneic effect), but cannot  suppress (negative allogeneic effect) bml2  B  cells in a ROLINK ET AL.  765 
primary anti-SRBC response. 4 Hence, it was concluded that, in vitro, the I-A mutation 
difference triggers alloreactive Tri cells and no, or almost no, alloreactive Ts cells.  4 
The data presented here indicate that an I-A incompatibility in vivo preferentially 
triggers the donor T  cells responsible for the induction of SLE-like GVHD (Table V); 
these T  cells are the alloreactive TH cells (8,  9)  possessing the Lyt-l+2  -  phenotype,  a 
Thus, both in vitro  4 and in vivo, an I-A difference triggers alloreactive donor TH cells 
and  no,  or  almost  no,  alloreactive  donor  Ts  cells.  In  the  latter  aspect,  the  I-A 
incompatibility differs from an incompatibility at  both I-A and K, which  causes a 
profound allosuppression both in vitro  4 and in vivo (Table V). 
In a  previous paper  (9), we showed  that  an  I-E difference between  the parental 
donor and F1  host  led  to the induction  of SLE-like GVHD. In vitro, the same I-E 
difference induced allohelp but no allosuppression. 4 Thus, both in vitro and in vivo 
(at  least  in  nonirradiated  F1  recipients),  class  II alloantigens  (I-A and  I-E)  trigger 
mainly alloreactive TH cells. It should be noted, however, that Swain and Dutton (30) 
were able to measure allosuppression across class II differences only; but, as opposed 
to our test system in vitro  4 and that of Cantor and Boyse (16), Swain and Dutton used 
a  population of primed spleen cells to which they added T  cells differing at class II 
alloantigens  (30).  Furthermore, Klein and Chiang  (15), who used F1 recipient mice 
that had been irradiated before the induction of GVHR, were able to induce LGVHD 
across class II differences only. It is unlikely though that LGVHD in that system was 
caused by alloreactive donor TH cells, because Lyt-l+2  -  donor cells were found to be 
incapable of inducing LGVHD in irradiated  F1 recipients across a  total H-2 differ- 
ence. 3 One possible explanation for the discrepancy in the outcome of the GVHR in 
irradiated and nonirradiated F1 mice differing at class II alloantigens is the difference 
in susceptibility to LGVHD in both kinds of F1 recipients.  Irradiated recipients are 
much  more  sensitive  than  nonirradiated  ones  for  the  induction  of LGVHD  (31). 
Therefore, it is possible that a  low amount of allosuppression, which is ineffective in 
nonirradiated F1 recipients, is effective in inducing LGVHD in irradiated F1 recipients. 
Neither Acute nor Stimulato(y  GVHD  Were Induced across a Mutational Difference at the K 
Locus Alone.  Lymphocytes from bml  and B6 produce a  positive mixed lymphocyte 
reaction in both directions (32), and bml-anti-B6 and B6-anti-bm 1 cytotoxic T  cells 
can also be generated (33,  34). Biochemical studies showed that the H-2K product of 
the bm 1 mutant differs from the product of B6 by only two amino-acid substitutions 
(35). 
In the present study, the GVHR across this small H-2K  b mutational difference was 
studied. Neither acute GVHD nor a full-blown SLE-like GVHD could be induced in 
the (B6 ×  bml)Fa mice by injection of the B6 donor cells (Table V). Similar results 
were obtained with combinations involving intra-H-2-recombinant strains that  dif- 
fered only at K  or D  (unpublished results). These findings indicate that a solely class 
I  (K mutation)  difference between  donor and  host  cannot  optimally trigger the T 
cells responsible for the induction  of stimulatory GVHD or the T  cells that  induce 
acute GVHD. A  possible explanation for this might be the relatively low amount of 
allohelp triggered by the H-2K  b mutation. Evidence from three different experimental 
systems clearly indicates that the induction of both acute and stimulatory GVHD in 
nonirradiated F1 mice requires strong allohelp (2,  20).a Although we  4 and others (36, 
37) showed that it is possible to generate allohelp as well as allosuppression across this 766  GRAFT-VS.  HOST  DISEASE MUTATIONS AT H-2K AND/OR  I-A 
H-2K  u mutation in vitro, the amount of allohelp was low when compared with the 
amount triggered by class II molecules.  4 
The lack of distinct  stimulatory and suppressive GVH symptoms triggered by the 
H-2K  u  mutation  cannot  be  ascribed  to  a  numerical  deficit  in  the  corresponding 
alloreactive  T  cells.  Swain  et  al.  (36)  reported  that  the  precursor  frequency  of 
alloreactive TH cells that  can be triggered by the  K  mutation difference of bml, is 
only a factor ~2 lower than the frequency of alloreactive TH cells triggered by a total 
H-2 difference. Nevertheless, we found that increasing the number of donor cells (1.6 
×  l0  s instead of 1 X  10  s B6 cells) injected into the (B6 ×  bml)F1 mice still failed to 
induce clear-cut stimulatory or suppressive GVHD (data not shown).  Alternatively, 
certain qualitative differences  4 between the allohelper T  cells triggered by class I  (K 
mutant)  and  class  II  (I-A  mutant)  might  account  for  the  observed  differences  in 
GVHD elicited by the I-A or I-A plus K  mutational differences on the one hand and 
the K  mutation alone on the other (Table V). 
Induction  of Acute  GVHD  across  a  K  Plus I-A  Difference.  Our  findings  show  that  a 
mutational difference at both I-A and K, but neither at I-A nor K  alone, triggers the 
donor T  cells capable of inducing acute GVHD (Table V). In previous papers (2-5) 3 
from our  laboratory, evidence has been  provided  that  acute  GVHD  is  due  to  the 
sequential activation of first alloreactive donor TH and eventually donor Ts cells. The 
data presented here strongly support this concept. The stimulatory symptoms observed 
in the (bm 1 ×  bm 12)F1 mice early after the injection of B6 donor cells can be ascribed 
to  alloreactive donor TH cells activated  by the  I-A mutation,  whereas  the  ensuing 
suppressive symptoms must have been caused by alloreactive donor Ts cells reacting 
to the K  mutation difference. Since no suppressive symptoms characteristic of acute 
GVHD could be induced across a K mutation difference alone, i.e., in the combination 
B6 ~  (B6 ×  bml)F1, obviously the alloreactive donor TH cells, triggered by the I-A 
incompatibility,  were  needed  for the  activation  of the  alloreactive  donor  Ts  cells. 
Thus, two signals  are required  for the optimal induction  of donor allosuppressor T 
cells in vivo: a class II difference (I-A mutation) that elicits maximal allohelp, and the 
additional existence of a class I difference (K mutation)  to which the donor Ts cells 
react. This requirement of both a  specific antigenic difference (class I) and maximal 
help elicited by a class II difference is identical with the requirements for the optimal 
activation of cytotoxic T  cells in vitro (38,  39).  Furthermore, the need of activated TH 
cells for the differentiation from Ts precursor to Ts effector cells follows the general 
rules of the T  cell circuit  formulated by Cantor and Gershon  (40).  Apparently, this 
sequence  of events  is  also  required  for the  induction  of the  allosuppressive effects 
characteristic of acute GVHD. 
The small antigenic  difference between GVH  (B6  X  bml2)F1 and GVH  (bml  × 
bm 12)'F1 mice deserves comment. Although this difference was restricted to but two 
amino acids in the K  molecule (35), it caused an extraordinary difference in patho- 
logical symptoms (Table V). Within  the spectrum of GVH symptoms (3), these two 
GVH combinations occupy exactly opposite positions, in that the former combination 
developed the stimulatory symptoms of SLE-like GVHD, whereas the latter developed 
the  pancytopenia  characteristic  of acute  GVHD.  As  we  shall  discuss  below,  this 
finding  might  be  able  to  improve our  understanding  of the  association  of certain 
immunological  diseases  with  structures  of the  major histocompatibility complex in 
man, HLA. ROLINK ET AL.  767 
Comparison with Etiologic Agents Causing GVHR-like  Pathological Changes.  Essentially 
the same spectrum of stimulatory and suppressive symptoms as that induced by the 
GVHR has been observed in patients exposed to sensitizing drugs or undergoing viral 
infections (3).  For instance, some of the patients sensitized to the drug diphenylhy- 
dantoin show hypergammaglobulinemia and SLE-like autoantibodies, whereas others, 
sensitized to the same drug, show hypogammaglobulinemia and/or aplastic anemia. 
A  similar GVH-like spectrum of different symptoms has been observed in patients 
infected with  Epstein-Barr virus  (3).  In  view of this  similarity of the pathological 
symptoms, it has been postulated that the basic cellular mechanism underlying these 
diseases might consist of GVH-like reactions of T  cells to autologous lympho-hemo- 
poietic cells or macrophages rendered foreign by the drug or the virus (3).  Evidence 
has been obtained from studies in mice that  indeed diphenylhydantoin attaches to 
the surface of lymphoid cells and then triggers GVH-like reactions by autologous T 
cells  (41,  42).  The GVHR  triggered  by small  mutational  changes  in  the  primary 
structure of class I and/or class II alloantigens, as studied in the present investigation, 
closely resembles this situation of "altered self." Conceivably, the combined recogni- 
tion by autologous T  cells of self-major histocompatibility complex (MHC) structures 
and  the  respective etiologic agent  might  cause  the  GVH-like diseases  observed in 
individuals undergoing viral infections or exposed to sensitizing drugs. Furthermore, 
our data indicate that possible somatic mutations that affect the MHC structures of 
lymphoid cells might also lead to GVH-like diseases. 
As has been discussed in detail elsewhere (9), products of the same locus, HLA-DR, 
appear to be involved in the pathogenesis of SLE, irrespective of whether the disease 
was idiopathic or induced by a  drug.  Because HLA-DR is a  functional analogue of 
the murine I-A/I-E loci (43), it is tempting to speculate that the cellular mechanism 
responsible  for  the  induction  of SLE  in  humans  is  the  same  as  the  mechanism 
responsible  for the  induction  of SLE-like GVHD  in  mice  (8,  9).  By analogy,  the 
spontaneous  development of suppressive GVH-like symptoms in  patients  might  be 
due to the combined recognition by autologous T  cells of the etiologic agent and class 
I as well as class II MHC structures. It is interesting, therefore, that in patients taking 
diphenylhydantoin a low serum IgA level was associated with an increased frequency 
of HLA-A2  (44).  Whether  there  also  exists  a  correlation  with  HLA-DR  in  such 
patients is not currently known. 
Summary 
By induction of a graft-vs.-host reaction (GVHR) in nonirradiated H-2-different F1 
mice, one can induce stimulatory pathological symptoms, such as lymphadenopathy 
and  hypergammaglobulinemia,  combined  with  the  production  of autoantibodies 
characteristic of systemic lupus erythematosus (SLE). Alternatively, the GVHR can 
lead to the suppressive pathological symptoms, such as pancytopenia and hypogam- 
maglobulinemia, characteristic of acute GVH disease (GVHD). Whether stimulatory 
or suppressive symptoms are induced by a GVHR depends, in our view (2-4), on the 
functional subset of donor T  cells activated in the F1 host. The purpose of the present 
study was to investigate whether class I and/or class II H-2 alloantigens can selectively 
trigger, out  of a  pool of unselected donor T  ceils, those subpopulations  of T  cells 
responsible for the stimulatory and suppressive GVH symptoms, respectively. 
For the induction of the GVHR,  l0  s lymphoid cells from C57BL/6  (B6)  donors 768  GRAFT-VS.-HOST  DISEASE MUTATIONS AT H-2K  AND/OR I-A 
were  injected  into  three  kinds  of F1  hybrid  mice,  which  had  been  bred  from  H-2 
mutant  strains  on  a  B6  background.  Whereas  the  I-A-disparate  (B6  X  bml2)F1 
recipiei~ts  exclusively  developed  stimulatory  GVH  symptoms,  including  SLE-like 
autoantibodies  and  immune complex glomerulonephritis,  the K  locus-disparate  (B6 
×  bml)F1 recipients showed neither clearly stinmlatory nor clearly suppressive GVH 
symptoms. In marked contrast, the (bml  ×  bml2)F1 recipients, which differ from the 
B6 donor strain by mutations at both K  and I-A locus, initially developed stimulatory 
GVH symptoms, but rapidly thereafter showed the suppressive pathological symptoms 
of acute GVHD and died. Moreover, spleen cells obtained from (B6 X bm 12)F1  mice 
injected  with  B6  donor  ceils  helped  the  primary  anti-sheep  erythrocyte  (SRBC) 
response of normal  (B6 ×  bml2)F1 spleen cells in vitro, whereas spleen cells  (bm l  x 
bml2)F1  mice  injected  with  B6  donor  cells  strongly  suppressed  the  primary  anti- 
SRBC response of normal (bml  ×  bml2)F1 spleen cells. Spleen cells from the K  locus- 
disparate  (B6 ×  bml)F~ recipients also suppressed the primary anti-SRBC of normal 
(B6 ×  bml)F1 spleen cells; this suppression, however, was weak when compared with 
the suppression induced by spleen cells from GVH  (bm 1 ×  bml2)F1 mice. 
Taken together, these findings indicate that a small class II (I-A) antigenic difference 
suffices to trigger the alloreactive  donor T  helper cells  causing SLE-like GVHD.  In 
contrast, both class I  (H-2K)  and class II (I-A) differences are required  to trigger the 
subsets  of donor T  ceils  responsible  for acute  GVHD.  It  appears  that  atloreactive 
donor T  helper cells induce the alloreactive T  suppressor cells, which then act as the 
suppressor  effector cells  causing  the  pancytopenia  of acute  GVHD.  These  findings 
may  help  to  understand  the  variability  of GVH-like  diseases  caused  by  a  given 
etiologic agent, their cellular pathogenesis, and association with certain HLA loci. 
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B6.C-H-2  bmlz. The technical assistance of Walter van der Meet, Deon Kanters, and Nellie de 
Boer-Bakker is gratefully acknowledged. Our colleagues Drs.  L. A.  Aarden,  P.  Ivimyi, C. J. 
Lucas, and C. J. M. Melief are thanked for their critical reading of the manuscript. 
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